期刊文献+

索利那新治疗双"J"管置入后尿路感染症状的疗效观察 被引量:2

Solifenacin Succinate Tablets Treatment Curative Effect Observation of Symptoms of Urinary Tract Infection after the Double "J" Tube
原文传递
导出
摘要 目的:观察琥珀酸索利那新对经皮肾镜碎石取石术患者术后留置双"J"管期间发生泌尿系统感染的疗效。方法:回顾性分析133例成功行经皮肾镜碎石取石术并常规留置双"J"管的患者,随机分为治疗组(n=67)和对照组(n=66)。治疗组给予索利那新片治疗,对照组仅给予饮水、休息等常规治疗。所有患者在置管5周后(拔管前一天)均随访并完成血、尿常规检验。结果:治疗组血、尿常规白细胞计数均低于对照组,治疗组均较对照组的泌尿系统的感染发生率低(P<0.05)。结论:口服索利那新能有效降低泌尿系统感染的可能性,降低患者在置管期间出现尿频、尿急、血尿、腰部疼痛、发热等并发症的概率,提高患者的生活质量,值得临床推广应用。 Objective: To observe the curative effect of the indwelling double "J" tube on the treatment of urinary tract infection in patients with percutaneous renal stone. Methods: A retrospective analysis of 133 cases who had taken the successful percutaneous lithotripsy and double "J" tube was conducted and the patients were randomly divided into the treatment group(n=67) and the control group(n=66). The patients in the treatment group were treated with the solifenacin succinate tablets, while the patients in the control group were treated with the regular methods, which including enough water and rest. Then the blood and urine examination were done after the treatment for five weeks. Results: The blood and urine leukocyte counts in the treatment group were lower than those of the control group, and the incidence of urinary infection in the treatment group was lower than that of the control group, and the differences were statistically significant(P〈0.05). Conclusions: Solifenacin succinate tablets can reduce the possibility of urinary tract infections,which can reduce the urgency, hematuria, flank pain, and fever, and improve the patient’s quality of life, which is worth of clinical application.
出处 《现代生物医学进展》 CAS 2016年第27期5290-5292,共3页 Progress in Modern Biomedicine
关键词 双"J"管 索利那新 泌尿系感染 Double "J" tubes Solifenacin succinate tablets Urinary tract infection
  • 相关文献

参考文献24

  • 1Chew BH, Knudsen BE, Denstedt JD, et al. The use of stents in con- temporary urology [J]. Current Opinion in Urology, 2004, 14 (2): 111-115.
  • 2H Jeong, C Kwak, SE Lee, et al. Ureteric stenting after ureteroscopy for uretefic stones: a prospective randomized study assessing symp- toms and complications [J]. Bju International, 2004, 93 (7): 1032-1034.
  • 3Julia F, Yige B, John GC, et al. The use of internal stents in chronicureteral obstruction [J]. The Journal of Urology, 2015, 193 (5): 1092-1100.
  • 4Giannarini G, Keeley FX Jr, Valent F, et al. Predictors of morbidity in patients with indwelling ureteric stents:results of a prospective study using the validated Ureteric Stent Symptoms Questionnaire [J]. BJU Int, 2011,107(4): 648-654.
  • 5陈燕,李金升,孟庆军,王瑞,乔保平,魏金星,文建国.索利那新治疗膀胱过度活动症4周疗效分析[J].第三军医大学学报,2011,33(1):104-105. 被引量:12
  • 6Chen Yah, Li Jin-sheng, Meng Qing-jun, et al. Ensuring that new bladder hyperactive disorder 4 weeks curative effect analysis[J]. Third military medical university journals, 2011, 33(1): 104-105.
  • 7Pediatric staghorn calculi: the role of extracorporeal shock wave lithotripsy monotherapy with special reference to ureteral stenting [J]. Urol, 2003, 169(2): 629-632.
  • 8Nabi G, Cook J. Outcomes of stenting after uncomplicated ureteros- copy: systematicreview and meta-analysis [J]. BMJ, 2007, 334(7593): 544-545.
  • 9Serati M, Braga A, Siesto G, et al. Risk factors for the failure of an- timuscarinie treatment wit I1 solifenacin in women with overactive bladder[J]. Urology, 2013, 82(4): 1044-1048.
  • 10Kawachi Y, Sakurai T, Sugimura S, et al. Long term treatment and prognostic factors of alpha 1 blockers for lower urinary tract symp- toms associated with benign prostatic hyperplasia: a pilot study com- paring naftopidil and tamsulosin hydrochloride [J]. Stand J Urol Nephrol, 2010, 44(1): 38-45.

二级参考文献23

  • 1Debruyne F M, Heesakkers J P. Clinical and socioeconomic relevance of overactive bladder[J]. Urology, 2004, 63(3 Suppl 1 ) : 42 -44.
  • 2Vardy M D, Miteheson H D, Samuels T A, et al. Effects of solifenacin on overactive bladder symptoms, symptom bother and other patient-reported outcomes: results from VIBRANT-a double-blind, placebo-controlled trial[J]. Int J Clin Pract, 2009, 63(12) : 1702 -1714.
  • 3Abrams P, Andersson K E. Muscarinic receptor antagonists for overactive bladder[J]. BJU Int,2007, 100(5) : 987 -1006.
  • 4Abrams P, Swift S. Solifenacin is effective for the treatment of OAB dry patients: a pooled analysis[J]. Eur Urol, 2005, 48(3) : 483 -487.
  • 5Prostatitis syndromes and sporting activities.Urologia,2010,77:126-138.
  • 6Effects of alphal adrenoceptor antagonist,naftopidil,on nonbacterial chronic pelvic pain syndrome in patients with lower urinary tract syndrome:evaluation of its efficacy using NIH-CPSI after 4-week treatment.Hinyokika Kiyo,2010,56:215 -219.
  • 7Sharp VJ,Takacs EB,Powell CR.Prostatitis:diagnosis and treatment.Am Fam Physician,2010,82:397-406.
  • 8Lipsky BA,Byren I,Hoey CT.Treatment of bacterial prostatitis.Clin Infect Dis,2010,50:1641-1652.
  • 9Hriz P,Danuser H,Studer UE,et al.Non-inflammatory chronic pelvic pain syndrome can be caused by bladder neck hypertrophy.Eur Urol,2003,44:106-110.
  • 10Ghobish AA.Quantitative and qualitative assessment of fiowmetrograms in patients with prostatodynia.Eur Urol,2000,38:576-583.

共引文献23

同被引文献14

引证文献2

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部